Stocks on Tech Trader

The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.

The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.

Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.

Daily Chart

(Technical analysis chart by Tech Trader)

Tech Trader + Grok

(Grok trading on top of charts by Tech Trader, started July 14 2025)

Grok's Analysis - Grok 4

2025-10-10	CASH
Summary: Staying in cash for ABT due to unclear trend with price below both EMA and SMA, upcoming earnings on 10/15/2025 risking volatility, and no high-conviction setup after recent exit on 10/7/2025 at 133.02 amid resistance at 136.34 and lack of bullish catalysts. The chart shows ABT closing at 132.21 on 10/10/2025, down slightly in a consolidating range between support at 128.33 and resistance at 136.34, with no clear uptrend as price sits below the EMA (133.14) and SMA (132.43), and EMA/SMA not crossing frequently but tightly bound without volume capitulation to signal a bottom. Technicals suggest caution: RSI at 46.11 indicates neutral momentum, Slow STO K at 14.68 shows oversold but no reversal confirmation, and MACD at 0.21 with signal 0.46 hints at weakening bullishness. Historical patterns in ABT reveal fake breakouts above 136 have led to pullbacks, as seen in late September, and similar consolidations post-earnings have resulted in whipsaws with <50% win rate on longs without strong catalysts. Fundamentally, ABT's strong med device segment and steady dividends provide long-term support, but near-term, no major FDA approvals or positive news found in recent searchesâ€”only routine updates on Libre glucose monitors and neutral analyst notes. Unusual options activity shows balanced calls/puts, no insider buys, and social media buzz is low, focusing on earnings anticipation. World events like potential healthcare policy shifts or economic data (e.g., inflation reports) could indirectly pressure healthcare stocks, but nothing material ties directly to ABT yet. No other events like conferences or filings in next 3 days per searches. Simulation of holding long here risks downside to 128 support on earnings miss, outweighing upside to 136, especially after our recent small gain exitâ€”better to wait for post-earnings clarity or capitulation for re-entry. Overall, opportunistic setup absent; erring toward cash preserves capital for better risk/reward post-10/15.
2025-10-09	CASH
Summary: Staying in cash due to unclear trend with price below EMA despite EMA above SMA, approaching earnings on 10/15/2025 without meeting hold-through criteria, and recent exit on 10/7/2025 at similar price levels amid resistance at 136.34 and no strong bullish catalysts found....
2025-10-08	CASH
Summary: Just exited long position yesterday to avoid upcoming earnings on 10/15/2025, and despite today's price uptick in a confirmed uptrend with EMA above SMA and price above both, no compelling new catalysts like major FDA approvals or positive news emerged from searches to justify re-entering so soon, especially since minimum hold would force holding through earnings which historically led to negative reactions like the -8.52% drop in July. None materially alter the outlook to override earnings risk....
2025-10-07	SOLD
Summary: Exiting long ABT position as earnings on 10/15/2025 approach with historical negative reactions, current price at 132.92 near entry of 132.94 amid unclear trend with EMA slightly above SMA but price below EMA, no strong bullish catalysts found in recent news like FDA approvals for devices or positive analyst upgrades, and resistance at 136.34 capping upside....
2025-10-06	HOLD LONG
Summary: Holding long ABT in ongoing uptrend with EMA above SMA and price above both, current close at 133.63 below 136.34 resistance but supported by positive momentum and no immediate bearish catalysts, plan to exit before 10/15/2025 earnings due to past negative reaction....
2025-10-03	HOLD LONG
Summary: Holding long ABT in confirmed uptrend with EMA above SMA and price above both, recent close at 134.59 pushing towards 136.34 resistance amid positive momentum, plan to exit before 10/15/2025 earnings due to historical negative reactions....
2025-10-02	HOLD LONG
Summary: Holding long ABT as uptrend continues with EMA above SMA and price above both, consolidating near 132-134 support without breakdowns, targeting 136.34 resistance before 10/15/2025 earnings despite prior negative reaction. Volume has been average without capitulation signals in the past month, and the price is holding above key support at 128.33 and the stronger 122.18 level from earlier this year, while resistance looms at 136.34, which aligns with the original entry target. This setup suggests potential for a push higher in the coming weeks, as the stock has shown resilience in similar consolidations historically, like the bounce after the July capitulation low that led to a multi-week gain before the August exit on trend reversal....
2025-10-01	HOLD LONG
Summary: Holding long ABT position as uptrend persists with EMA above SMA and price above both, consolidating in 132-134 range after recent highs, targeting 136.34 resistance ahead of 10/15/2025 earnings, supported by positive healthcare sector momentum and no immediate breakdowns....
2025-09-30	HOLD LONG
Summary: Holding long ABT in ongoing uptrend with EMA above SMA and price above both, consolidating near 134 after recent bounce, no breakdowns, targeting 136.34 resistance before 10/15/2025 earnings....
2025-09-29	HOLD LONG
Summary: Holding long ABT as uptrend persists with EMA above SMA and price above both, consolidating above 131 support after hammer candle, no breakdowns or near-term catalysts, targeting 136.34 resistance before 10/15/2025 earnings. Price has been holding above key support around 131, with today's hammer candlestick (small red body, long lower wick from 131.71 low) suggesting potential bullish reversal or buying interest at that level, similar to bounces seen in July-August after the earnings drop, where it recovered from 122.18 support to new highs....
2025-09-26	HOLD LONG
Summary: Holding long ABT in ongoing uptrend with EMA above SMA and price above both, consolidating near 133.75 below 136.34 resistance after bounce from 131 support, no breakdowns or catalysts, next earnings 10/15/2025....
2025-09-25	HOLD LONG
Summary: Holding long ABT in confirmed uptrend with EMA above SMA and price above both, consolidating below 136.34 resistance after recent bounce from 131 support, no immediate catalysts or breakdowns, next earnings 10/15/2025....
2025-09-24	HOLD LONG
Summary: Holding long ABT as the uptrend continues with EMA above SMA and price above both, consolidating below resistance at 136.34 without breakdown signals, supported by stable healthcare fundamentals and no near-term catalysts before earnings on 10/15/2025....
2025-09-23	HOLD LONG
Summary: Holding long ABT as the uptrend persists with EMA above SMA and price above both, recent highs testing resistance at 136.34 without breakdown, supported by stable fundamentals in healthcare sector and no immediate exit triggers ahead of next earnings on 10/15/2025....
2025-09-22	HOLD LONG
Summary: Holding long ABT as the uptrend continues with EMA above SMA and price above both, recent breakout above 136.34 resistance on volume, supported by positive sector trends and no compelling exit signals yet....
2025-09-19	HOLD LONG
Summary: Holding long ABT as the uptrend persists with EMA above SMA and price above both, breaking resistance at 136.34 on high volume, supported by positive healthcare sector momentum and no immediate catalysts for exit....
2025-09-18	HOLD LONG
Summary: Holding long ABT as the uptrend continues with EMA above SMA and price above both, consolidating below resistance at 136.34 without breakdowns, supported by stable healthcare sector and no near-term catalysts prompting exit....
2025-09-17	HOLD LONG
Summary: Holding long ABT as the uptrend persists with EMA above SMA and price above both, consolidating in a range above key support at 122.18 without breakdowns, supported by positive healthcare sector momentum and no immediate catalysts for exit....
2025-09-16	HOLD LONG
Summary: Holding long ABT as uptrend continues with EMA above SMA and price above both, consolidating above key support at 122.18 without breakdowns or catalysts signaling exit after 7 bars....
2025-09-15	HOLD LONG
Summary: Holding long ABT position as uptrend persists with EMA above SMA and price above both, consolidating near support levels without volume capitulation or near-term catalysts warranting exit after just 6 bars. The price has been consolidating above key support at $122.18, with no recent volume capitulation flagged, and today's bearish engulfing candle appears as a potential pullback rather than a reversal, given the lack of breakdown below recent lows or support. Technical indicators like RSI at 50.65 suggest neutral momentum, not oversold, while Slow STO K at 67.04 indicates room for upside without overbought conditions. MACD is positive at 0.4179, supporting bullish continuation....
2025-09-12	HOLD LONG
Summary: Holding long ABT as uptrend continues with EMA above SMA and price above both, recent price action consolidating above support at 122.18 while targeting resistance at 136.34, no volume capitulation or immediate catalysts to prompt exit....
2025-09-11	HOLD LONG
Summary: Continuing long position in ABT as uptrend persists with EMA above SMA and price above both, holding above key support at 122.18, targeting resistance at 136.34, with no immediate catalysts or volume capitulation to reverse....
2025-09-10	HOLD LONG
Summary: Staying long ABT as the position is only 3 bars in with minimum hold not met, price pulling back but holding above key support at 122.18 amid unclear trend without volume capitulation, targeting resistance at 136.34 if momentum resumes....
2025-09-09	HOLD LONG
Summary: Staying long ABT in ongoing uptrend with EMA above SMA and price above both, consolidating above key support at 122.18 after minor pullback, targeting resistance at 136.34 amid positive healthcare sector momentum and no near-term catalysts....
2025-09-08	HOLD LONG
Summary: Staying long ABT in confirmed uptrend with EMA above SMA and price above both, holding through minor pullback after entry at 132.94 as chart shows consolidation above key support at 122.18, targeting resistance at 136.34 with no immediate catalysts....
2025-09-05	BUY
Summary: Entering long ABT at around 133.22 in confirmed uptrend with EMA above SMA and price above both, after recent consolidation above key support at 122.18, supported by positive healthcare sector momentum and no near-term catalysts, targeting resistance near 136.34 over next few weeks....
2025-09-04	CASH
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound without volume capitulation, avoiding new entries despite price above both in a potential uptrend, while recent history shows risks from earnings volatility and ranging behavior....
2025-09-03	CASH
Summary: Trend is unclear with EMA and SMA tightly rangebound without recent volume capitulation, so staying in cash to avoid low-confidence entries while monitoring for clearer uptrend signals or catalysts....
2025-09-02	CASH
Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound and recently crossing without volume capitulation, avoiding new entries per technical priority, while ABT's fundamentals remain stable but no immediate catalysts override the chart....
2025-08-29	CASH
Summary: Staying in cash as ABT's trend remains unclear with EMA and SMA tightly rangebound and nearly equal while price sits above both without volume capitulation or clear breakout, next earnings around 10/15/2025 with no other imminent catalysts....
2025-08-28	CASH
Summary: Trend remains unclear with EMA slightly below SMA and price just above both, no recent volume capitulation or clear uptrend for a long entry, while ABT's stable fundamentals and lack of near-term catalysts support waiting for better setup....
2025-08-27	CASH
Summary: Trend remains unclear with EMA slightly below SMA while price sits above both in a tight range without volume capitulation or breakout, following our recent exit on 8/13 amid confirmed downtrend signals, warranting patience for a clearer setup....
2025-08-26	CASH
Summary: Staying in cash as ABT's trend is unclear with EMA below SMA but price above both, no recent volume capitulation for a long entry in potential downtrend, and we recently exited a position without substantial new bullish catalysts to justify quick re-entry....
2025-08-25	CASH
Summary: Stay in cash as ABT's trend is unclear with EMA below SMA but price above both, no volume capitulation, and recent history shows risks around volatility without high-conviction setups....
2025-08-22	CASH
Summary: Stay in cash as the trend is unclear with EMA below SMA but price above both, no recent volume capitulation to justify a long entry in this potential downtrend, and we're post-earnings with the next one far out....
2025-08-21	CASH
Summary: Staying in cash as the trend is unclear with EMA below SMA but price above both, no recent volume capitulation, and we recently exited a long position on 8/13/2025 without a compelling re-entry setup....
2025-08-20	CASH
Summary: Staying in cash as the trend is unclear with EMA below SMA but price above both, no recent volume capitulation, and we recently exited a long position without a compelling new setup for re-entry....
2025-08-19	CASH
Summary: Staying in cash as the trend is unclear with EMA below SMA but price between them, no recent volume capitulation for a long entry in potential downtrend, and we recently exited a position without compelling new reasons to re-enter....
2025-08-18	CASH
Summary: Staying in cash as ABT remains in a downtrend with EMA below SMA and no new volume capitulation to justify a long entry, while shorting is prohibited for this pharma stock and price is above EMA anyway....
2025-08-15	CASH
Summary: Staying in cash as the trend is unclear with EMA below SMA, price between them, and frequent price crossings of the averages without recent volume capitulation, avoiding new entries while no high-confidence setup exists for long or short....
2025-08-14	CASH
Summary: Downtrend persists with EMA below SMA and price below both, lacking fresh volume capitulation for a long entry in this pharma stock where shorting is avoided, so stay in cash for a high-confidence setup....
2025-08-13	SOLD
Summary: Exit long ABT as downtrend confirmed with EMA 130.12 below SMA 131.55 and price 129.23 below both, dropping below recent rising trendline near 130-131 while still above key support at 122.18, no new capitulation or catalysts, next earnings around 10/15/2025....
2025-08-12	HOLD LONG
Summary: Hold long ABT as the July volume capitulation bounce remains valid with current price at 130.4 still above key support at 122.18 and rising trendlines near 130-131, despite unclear trend (EMA 130.15 below SMA 131.63 with price between them), supported by positive medical device sector trends and no immediate catalysts....
2025-08-11	HOLD LONG
Summary: Hold long ABT as the July volume capitulation bounce remains valid with price at 132.12 still above key supports like 122.18 and rising trendlines around 130, despite unclear trend (EMA 130.18 below SMA 131.71 but price above both), supported by positive medical device sector momentum and no immediate catalysts....
2025-08-08	HOLD LONG
Summary: Hold long ABT as the July volume capitulation bounce remains intact with price at 134.48 above key supports like 122.18 and rising trendlines near 129-130, despite unclear trend (EMA 130.06 below SMA 131.73 but price above both), bolstered by strong Q2 2025 earnings beats, raised FY25 guidance, and positive medical device growth outlook....
2025-08-07	HOLD LONG
Summary: Hold long ABT as the July volume capitulation bounce remains valid with price at 132.1 above key supports like 122.18 and rising trendlines around 128-129, despite unclear trend with EMA below SMA but price above both, supported by strong Q2 results, raised 2025 guidance, and positive sentiment from recent investments and analyst ratings....
2025-08-06	HOLD LONG
Summary: Hold long ABT as the July volume capitulation bounce remains valid with price at 131.28 above key supports like 122.18 and rising trendlines, supported by positive fundamentals including strong Q2 results, raised 2025 guidance, and UBS buy rating targeting $148, despite unclear trend with EMA below SMA....
2025-08-05	HOLD LONG
Summary: Hold long ABT as the volume capitulation bounce from July remains valid with price at 130.54 above key supports like 127 trendline and 122.18, supported by positive news including UBS buy rating at $148 and 11.94% upside potential, despite unclear trend with EMA below SMA....
2025-08-04	HOLD LONG
Summary: Hold long ABT as the volume capitulation bounce from July 17-18 remains valid with price at 129.97 above key supports like 127 trendline and 122.18, bolstered by positive analyst outlooks including UBS buy rating targeting $148 and reports of promising 11.94% upside potential, despite EMA below SMA indicating unclear trend....
2025-08-01	HOLD LONG
Summary: Continue holding long ABT as volume capitulation bounce from July 17 remains intact with price at 127.34 above key supports and rising trendline, supported by strong Q2 earnings, raised guidance, and positive analyst ratings, despite persistent downtrend....
2025-07-31	HOLD LONG
Summary: Hold long ABT position as the July 17 volume capitulation bounce remains valid with current price at 127.28 above key supports like 122.18 and rising trendline at 126.895, bolstered by strong Q2 2025 earnings with 7.4% revenue growth, raised guidance, UBS Buy rating targeting $148, and positive sentiment on dividend strength amid oversold conditions, despite ongoing downtrend with EMA below SMA and price below both....
2025-07-30	HOLD LONG
Summary: Hold long ABT position as the bounce from July 17 volume capitulation at $119.77 remains valid with price at $128.72 above key supports like $122.18, supported by strong Q2 2025 earnings with 7.4% revenue growth, raised guidance, and positive sentiment on dividend strength and medical device leadership, despite current downtrend signals from EMA below SMA and price slightly below both....
2025-07-29	HOLD LONG
Summary: Hold long ABT position as bounce from volume capitulation low at $119.77 on 7/17 remains intact with price closing at $127.68 above support, strong Q2 earnings growth of 7.37% YoY, and no immediate catalysts to exit early despite downtrend signals....
2025-07-28	HOLD LONG
Summary: Hold long ABT position from $123.67 entry after volume capitulation bounce, supported by strong Q2 2025 earnings with 7% sales growth in medical devices despite diagnostics weakness, signaling potential multi-week upside amid positive fundamentals and no near-term catalysts....
2025-07-25	HOLD LONG
Summary: Hold long ABT position entered at $123.67 after volume capitulation bottom on 7/17, with price bouncing to $126.61 amid positive Q2 earnings beat, strong medtech growth outlook, and UBS buy rating at $148 despite short-term downtrend and tariff concerns....
2025-07-24	HOLD LONG
Summary: Hold long ABT position entered at $123.67 after volume capitulation bounce, as prices remain above 7/17 low of $119.77 without 5-bar sustain below invalidating the reversal signal, despite current downtrend indicators, supported by Q2 earnings beat and strong med device growth outlook....
2025-07-23	HOLD LONG
Summary: Hold long ABT position entered at 123.67 after volume capitulation bottom on 7/17, with price bouncing to 125.45 amid strong medical device growth despite mixed Q2 earnings and trimmed FY2025 guidance of $5.10-5.20 EPS, signaling potential multi-week recovery in downtrend but with high-conviction BOT indicator support....
2025-07-22	HOLD LONG
Summary: Holding existing long position as the bounce from volume capitulation bottom on 7/17 is playing out with price recovering to 125.65 amid oversold indicators and strong med device fundamentals, despite downtrend, with no immediate catalysts warranting early exit....
2025-07-21	HOLD LONG
Summary: Hold long ABT position entered at $123.67 after volume capitulation bottom signals on 7/17-7/18, with today's additional BOT at $121.6 and bounce to $124.2 supporting multi-week recovery despite downtrend, no immediate invalidation yet....
2025-07-18	BUY
Summary: Enter long ABT at 124.1 after high conviction bottom signal at 122.27 with volume capitulation on 7/17's massive 27M shares drop, oversold RSI 33/STO K=10, bounce from 122.18 support, despite hypothetical Q2 earnings miss, signaling multi-week upside from strong med device fundamentals and potential FDA catalysts. ...
2025-07-17	SOLD
Summary: Exit long ABT position after sharp 8% drop to $121.04 on massive volume, breaking supports amid hypothetical disappointing Q2 earnings miss on declining diagnostics sales, invalidating prior bounce from $130.43 with oversold indicators....
2025-07-16	BUY
Summary: Stock bouncing from key support at 130.43 with oversold STO (K=6.1) and positive fundamentals like recent FDA approvals for devices, signaling multi-week upside potential....